BioSpace News Archive

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that on November 14, 2022 it priced an offering of €1.25 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes.

Microvi announced today that it has been awarded over $1.1M in funding from the National Institute of Health (NIH) to scale-up its newly developed technology to eliminate chromium, a cancer-causing chemical, in drinking water.

DAXOR CORPORATION, the global leader in blood volume measurement technology, announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share.

Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, reports initial positive results from the single ascending dose (SAD) arm of the Phase 1 study of its melanocortin‐3/4 antagonist peptide candidate, TCMCB07, for the treatment of cachexia.

CardieX Limited, a global health technology company focused on cardiovascular disease, announced that it has acquired all the assets of Blumio, Inc., a Silicon Valley based developer of advanced algorithms and technology for cardiovascular sensors, signifying the company’s continued investment in cardiovascular health monitoring technologies.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

Precision Optics Corporation, Inc. announced that the Company has been approved to list on the Nasdaq Capital Market, and that trading on the Nasdaq is expected to begin on Wednesday, November 16, 2022, under the symbol “POCI.” The Company’s shares will continue to trade on the OTCQB until trading on Nasdaq commences.

AEYE Health, a leading company for AI-based retinal imaging and diagnostics, is pleased to announce that it received a 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market its diagnostic screening system for diabetic retinopathy.